Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.
BACKGROUND
There is growing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of solid tumors. Colorectal cancer results from the cumulative effect of sequential genetic alterations, leading to the expression of tumor associated antigens possibly inducing a cellular anti-tumor immune response. It is well recognized that cytotoxic lymphocytes constitute one of the most important effector mechanisms of anti-tumor-immunity. However, their potential prognostic influence in colorectal cancer remains controversial. Aim of the study was to examine infiltration of CD3+ and CD8+ lymphocytes in colorectal cancer and their prognostic potential.Two-hundred-fifteen colorectal cancer cases, previously analyzed for microsatellite instability (MSI), were selected for immunohistochemical detection of CD3+, CD8+ infiltration and the expression of granzyme B. Prognostic relevance was assessed by survival analysis.


RESULTS
Strong correlations were found between the infiltration of lymphocytes and several clinicopathological variables. Survival analysis revealed that intra-epithelial infiltration of CD3+ and CD8+ T lymphocytes and stromal infiltration of CD3+ lymphocytes had a major impact on the patients' overall survival in the univariate analysis, however independent of their association with MSI-status. In addition, it was also demonstrated that there was an important disease specific survival advantage for patients with microsatellite stable (MSS) tumors containing intraepithelial CD8+ tumor infiltrating lymphocytes. When samples were analyzed for colon cancer and rectal cancer separately, the results of the overall population were confirmed in colon cancer only. When entered into a multiple Cox regression analysis adjusting for other possible important confounding factors, the strong impact of lymphocyte infiltration on overall survival was not maintained. Only early stage and young age (borderline significant for overall population only) were associated with a better overall survival (early disease with disease-free survival also).


CONCLUSIONS
In conclusion our results suggest a role for infiltrating CD3+ and CD8+ T lymphocytes in colorectal cancer whereby tumor infiltration could reflect a general principle of antitumor immunity, irrespective of the MSI-status.
Deschoolmeester
Vanessa
V
Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp (UA/UZA), Wilrijk, Belgium. vanessa.deschoolmeester@ua.ac.be
Baay
Marc
M
Van Marck
Eric
E
Weyler
Joost
J
Vermeulen
Peter
P
Lardon
Filip
F
Vermorken
Jan B
JB
D000368:Aged; D014408:Biomarkers, Tumor / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged
D014408:Biomarkers, Tumor
Br J Cancer. 2004 Nov 1;91(9):1711-7
15494715
Science. 2006 Sep 29;313(5795):1960-4
17008531
Lancet. 1999 Jan 30;353(9150):345-50
9950438
Eur J Cancer. 2007 Feb;43(3):624-31
17223543
Int J Cancer. 2006 Apr 1;118(7):1721-7
16231316
Am J Pathol. 1999 Jun;154(6):1805-13
10362805
Recent Results Cancer Res. 2005;165:260-7
15865042
Cancer. 2001 Jun 15;91(12):2417-22
11413533
Cancer Immun. 2007 Mar 28;7:7
17388261
Cancer Immunol Immunother. 2002 Jul;51(5):235-47
12070710
J Clin Oncol. 2005 Jan 20;23(3):609-18
15659508
Am J Pathol. 1998 Oct;153(4):1063-78
9777938
Int J Cancer. 2001 Jul 1;93(1):6-11
11391614
Clin Colorectal Cancer. 2007 Nov;6(10):683-90
18039421
Aliment Pharmacol Ther. 2006 Oct 15;24(8):1163-77
17014575
J Clin Lab Anal. 2006;20(2):52-61
16538640
World J Surg Oncol. 2005 May 12;3:26
15890075
Oncology. 2003;64(3):259-65
12697967
Br J Cancer. 2005 May 9;92(9):1746-53
15856045
Hum Pathol. 1999 Jun;30(6):629-34
10374769
JAMA. 1990 Sep 19;264(11):1444-50
2202842
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Oncol Rep. 2005 Jul;14(1):241-9
15944796
Int J Cancer. 2006 Jan 1;118(1):6-10
16003753
Lancet. 2005 Jan 8-14;365(9454):153-65
15639298
Eur J Cancer. 2009 Aug;45(12):2138-45
19409772
Br J Surg. 2004 Apr;91(4):469-75
15048750
Hum Pathol. 2004 Jul;35(7):808-16
15257543
Gastroenterology. 2008 Apr;134(4):988-97
18395080
Am J Pathol. 2001 Jul;159(1):297-304
11438476
Cancer Res. 2003 Sep 1;63(17):5564-72
14500396
Cancer Immunol Immunother. 2008 May;57(5):601-9
17874100
Crit Rev Immunol. 1995;15(3-4):359-84
8834456
Cancer Res. 2009 Mar 15;69(6):2685-93
19258510
J Pathol. 1997 Jul;182(3):318-24
9349235
Br J Cancer. 1999 Sep;81(2):190-3
10496341
Br J Cancer. 2005 Feb 28;92(4):651-4
15700032
Gut. 2000 Feb;46(2):200-4
10644313
J Pathol. 1999 Dec;189(4):487-95
10629548
Eur J Cancer. 2008 Oct;44(15):2288-95
18707864
Cancer Res. 2007 Mar 1;67(5):1883-6
17332313
Jpn J Clin Oncol. 2004 Feb;34(2):90-8
15067103
Cancer Immunol Immunother. 2003 Jul;52(7):423-8
12695859
Eur J Cancer. 2005 Nov;41(17):2645-54
16239109
Fam Cancer. 2009;8(3):231-9
19165625
J Pathol. 1999 May;188(1):14-7
10398134
Lab Invest. 2004 Apr;84(4):493-501
14968119
N Engl J Med. 2005 Dec 22;353(25):2654-66
16371631
Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3
17122624
J Mol Diagn. 2008 Mar;10(2):154-9
18258928
Ann Surg. 2009 May;249(5):788-93
19387324
Cancer Res. 1998 Aug 15;58(16):3491-4
9721846
Gut. 2001 Mar;48(3):360-6
11171826
Eur J Cancer. 2007 Jun;43(9):1348-60
17512720
Ann Oncol. 2004 Feb;15(2):242-6
14760116
Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57
12672517
Br J Cancer. 2004 Jun 1;90(11):2053-8
15164120
Cancer Immun. 2009 Feb 19;9:1
19226101
Cancer Biother Radiopharm. 2009 Jun;24(3):369-76
19538060
N Engl J Med. 2005 Dec 22;353(25):2640-1
16371629
Lancet. 1987 Jun 6;1(8545):1303-6
2884421
Oncol Rep. 2003 Mar-Apr;10(2):309-13
12579264
Semin Oncol. 1995 Dec;22(6):600-10
8539635